10 Best High Tech Stocks To Buy For 2014

In many ways it seems like a silly question: Of course General Motors (NYSE: GM  ) is an American company. GM's headquarters is here, it has massive manufacturing and design operations here, and brands like Chevrolet and Cadillac are about as American as brands get.

But from an investing perspective, is that really the right way to think about GM nowadays? In this video, Fool.com contributor John Rosevear looks at the increasing importance of GM's non-U.S. operations ���nd at why anyone considering an investment in GM needs to take much more than the American market into account.

China is already the world's largest auto market ��and it's set to grow even bigger in coming years. A recent Motley Fool report, "2 Automakers to Buy for a Surging Chinese Market", names two global giants poised to reap big gains that could drive big rewards for investors. You can read this report right now for free ��just click here for instant access.

Best European Stocks To Buy Right Now: Siebert Financial Corp.(SIEB)

Siebert Financial Corp., through its subsidiary, Muriel Siebert & Co., Inc., engages in the retail discount brokerage and investment banking operations in the United States. The company provides Internet and traditional discount brokerage and related services to retail investors; independent retail execution services; and retail customer services. It also offers various self-directed retirement accounts, for which it acts as agent on various transactions; and lends customers a portion of the market value of certain securities held in the customer?s account through its clearing agent. In addition, the company, through its other subsidiary, Siebert Woman?s Financial Network, Inc., provides products, services, and information to serve women?s financial needs. Further, Siebert Financial Corp. offers equity execution services on an agency basis, as well as equity and fixed income underwriting and investment banking services to institutional investors, and issuers of equity a nd fixed-income securities. The company provides its discount brokerage services through a broker on the telephone, through a wireless device, or via the Internet. It maintains seven retail discount brokerage offices in New York; Jersey City, New Jersey; Boca Raton, Surfside, West Palm Beach, and Naples, Florida; and Beverly Hills, California. The company was founded in 1886 and is headquartered in New York, New York.

Advisors' Opinion:

• [By Jon C. Ogg]

  Muriel Siebert, founder of Siebert Financial Corp. (NASDAQ: SIEB), passed away over the weekend. Many new investors may not know her nor may they know just how important and influential she was on Wall Street and in the financial services industries. Ms. Siebert died at the age of 80 years old, and we wanted to list some of her accomplishments that have led to at least more equality among women in what had been a men-only club before she came on the stage.

10 Best High Tech Stocks To Buy For 2014: Guidewire Software Inc (GWRE)

Guidewire Software, Inc. (Guidewire), incorporated in 2001, is a provider of system software to the global property and casualty insurance industry. The Company�� solutions serve as the transactional systems-of-record for, and enable the functions of a property and casualty insurance carrier�� business, such as underwriting and policy administration, claims management and billing. Guidewire has developed a suite of configurable applications that are delivered through a Web-based interface and can be deployed either on-premise or in cloud environments. Its Guidewire InsuranceSuite includes Guidewire PolicyCenter, Guidewire ClaimCenter and Guidewire BillingCenter applications, which enable a range of property and casualty insurance operations. The Company derives its revenues from licensing software applications, providing maintenance support and providing professional services, principally consisting of implementation and training services. Guidewire�� license revenues are primarily generated through annual license fees. In May 2013, Guidewire Software Inc acquired Millbrook Inc.

Guidewire PolicyCenter

Guidewire PolicyCenter is the Company�� underwriting and policy administration application that serves as a system-of-record that supports the policy lifecycle, including product definition, underwriting, quoting, binding, issuances, endorsements, audits, cancellations and renewals. PolicyCenter integrates the underwriting process of evaluating risks and establishing the appropriate policy terms and pricing.

Guidewire ClaimCenter

Guidewire ClaimCenter is the Company�� claims management application for claim intake, assessment, settlement and processing of claim-related financial transactions. ClaimCenter provides property and casualty insurance carriers with the tools built within a business rules-based claims application.

Guidewire BillingCenter

Guidewire BillingCenter is its billing and receivables management a! pplication. It automates the billing lifecycle, enables the design of a range of billing and payment plans, manages agent commissions and integrates with external payment systems. BillingCenter handles direct and agency billing for all property and casualty insurance lines of business, and its dual-entry accounting core integrates with a property and casualty insurance carrier�� general ledger.

The Company competes with Accenture, Computer Sciences Corporation, MajescoMastek, Tata Consultancy Services Limited, AQS, Inc., OneShield, Inc., StoneRiver, Inc., Oracle Corporation, Pegasystems Inc. and SAP AG.

Advisors' Opinion:

• [By Eric Volkman]

  Guidewire Software (NYSE: GWRE  ) results for the company's fiscal Q3 have been released. For the quarter, revenue was $68 million, an improvement over the $57 million it posted in the same period the previous year. The bottom line turned red, however, swinging to a loss of $2.7 million ($0.05 per diluted share) from Q3 2012's profit of $3.1 million ($0.05).�

• [By Jonas Elmerraji]

  It doesn't get much more simple than the setup in shares of Guidewire Software (GWRE). You don't have to be an expert technical analyst to figure out what's going on in this stock. All it takes is a quick look at the chart.

  Guidewire is currently trending higher in a well-defined price channel, a setup that gives us a high probability price range for GWRE's shares to trade within. Now, with shares sitting at trendline support, we're coming on a timely buying opportunity; buying at support has proven prescient each of the last six times GWRE has tested the support level that it established in March. But it's still critical to wait for the bounce in shares.

  Buying off a support bounce makes sense for two big reasons: it's the spot where shares have the furthest to move up before they hit resistance, and it's the spot where the risk is the least (because shares have the least room to move lower before you know you're wrong). Remember, all trend lines do eventually break, but by actually waiting for the bounce to happen first, you're ensuring the Guidewire can actually still catch a bid along that line.

10 Best High Tech Stocks To Buy For 2014: BT Group plc (BT)

BT Group plc provides communications solutions and services worldwide. It engages in the provision of networked IT services; and local, national, and international telecommunications services for use at home, at work, and on the move. The company also offers broadband and Internet products in the United Kingdom (U.K.), as well as TV and converged fixed/mobile services. It operates in four segments: BT Global Services, BT Retail, BT Wholesale, and Openreach. The BT Global Services segment provides managed networked IT services to multinational corporations, domestic businesses, and national and local government organizations. The BT Retail segment offers broadband, telephony, and TV services, as well IT and telephony for small to medium sized businesses in the United Kingdom. It also provides video and telephone conferencing, CCTV, and alarm systems. This segment serves corporate, small and medium enterprises, consumer, and wholesale markets in the U.K., the Republic of Ire land, and Northern Ireland. The BT Wholesale segment provides voice, broadband, and data communications services, including managed services for fixed and mobile network operators, Internet service providers, and telecoms resellers in the U.K. The Openreach segment connects communications providers? customers to their local telephone exchange, giving them access to the U.K. network. The company was formerly known as Newgate Telecommunications Limited and changed its name to BT Group plc in September 2001. BT Group plc was founded in 1981 and is based in London, the United Kingdom.

Advisors' Opinion:

• [By Royston Wild]

  Today I am looking at�BT Group� (LSE: BT-A  ) (NYSE: BT  ) to see how it measures up.

  What are�BT Group's earnings expected to do?

• [By Tony Reading]

  LONDON -- Things are getting personal between�BT� (LSE: BT-A  ) (NYSE: BT  ) and�Sky� (LSE: BSY  ) . The telecoms company is muscling in on Sky's lucrative sports channel business, and the 39% News Corp.-owned pay-TV broadcaster doesn't like it.

• [By Alex Jordon]

  A variety of acquisitions ramps up Oracle's presence in cloud computing, like deals with RightNow, Taleo, and Eloqua. The annual run-rate of their cloud business is already over $1 billion, larger than Workday (WDAY) and SAP (SAP) combined. New customers include British Telecom (BT), BMC Software (BMC), Siemens (SI), Yahoo (YHOO), and Intuit (INTU).

• [By Jose Pagliery]

  Currently, 36% of companies have a BYOD policy, according to networking giant Cisco (CSCO, Fortune 500) and the British telecom BT (BT).

  Companies quiet about hacks: The study also found that 57% of IT analysts say they've confronted a data breach that the company decided to keep secret from customers, partners or shareholders.

10 Best High Tech Stocks To Buy For 2014: Bell AG (BELL)

Bell AG is a Switzerland-based company that is primarily engaged in the production and distribution of meat. The Company has seven product groups. The Fresh Meat product group is involved in the supply of self-service meat products for the retail trade and products for the restaurant trade, as well as Vaudois specialties. The Charcuterie (own and purchased) product groups offer ready-cooked products, both under the Bell brand and under a number of customers' own brands. The Poultry product group offers various poultry products, as well as specialty meats, such as rabbit, game, ostrich and kangaroo. The Convenience product group offers ready-cooked seasonal convenience products, such as domestic and imported fish. Within the Seafood product group, the Company offers fresh and frozen seafood. Bell AG�� brands include Abraham, Zimbo and Polette, among others. The Company operates subsidiaries in Switzerland, Germany, France, Spain, Belgium, Hungary and other countries. Advisors' Opinion:

• [By Tannor Pilatzke]

  Investment ideas are scarce and hard to come by at times. People constantly ask me about companies they work for (Bell) or businesses they purchase a lot of product from (P&G or Coca-Cola), and what I think about the prospects/valuation. When it is not the blue chips in the limelight it certainly is the Netflix��,Tesla's, 3-D printing, and other companies I would classify as speculative. It is not that I am a Grinch, but I do not like giving out investment ideas. Rather, I attempt to give lessons. As Maimonides said, ��ive a man a fish, feed him for a day; teach a man to fish and feed him for a lifetime.��/p>

10 Best High Tech Stocks To Buy For 2014: Pharmacyclics Inc (PCYC)

Pharmacyclics, Inc., incorporated on April 19, 1991, is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. As of June 30, 2011, it had three drug candidates under clinical development and a number of preclinical lead molecules. This includes an inhibitor of Bruton�� tyrosine kinase (Btk) (PCI-32765) in Phase II studies in hematologic malignancies; a Btk inhibitor lead optimization program targeting autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer, and a histone deacetylase (HDAC) inhibitor (PCI-24781) in Phase I and II clinical trials in solid tumors and hematological malignancies as of June 30, 2012.

As of June 30, 2012, the Company developed ibrutinib, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a variety of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse B-cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its current or planned Phase Ib/II and Phase III development program. had development programs for B-cell malignancies and autoimmune diseases. For malignant indications it has developed PCI-32765, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its Phase II development. It has developed an assay! to measure occupancy of Btk in PBMCs using a cell-permeable fluorescently-labeled derivative of PCI-32765.

Factor VII is an enzyme that becomes activated (FVIIa) by binding to the cell surface protein tissue factor (TF), a protein found in the body that helps to trigger the process of blood clotting in response to injury. TF is over expressed in many cancers including gastric, breast, colon, lung, prostate, ovarian and pancreatic cancers. In these tumors, the FVIIa/TF complex induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2), another cell-surface protein. This in turn increases the expression of interleukin-8 (IL-8), a protein produced by white blood cells and other immune cells in response to pathogenic stimulation, and vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate the growth of blood vessels. Both proteins play an important role in tumor growth and metastases as well as angiogenesis (growth of new blood vessels). FVIIa/TF complex also initiates the coagulation (a process by which blood forms clots) processes implicated in the high incidence of thromboembolic (the process by which the blood clots within a blood vessel) complications seen in patients with TF-expressing cancers. Thromboembolic events are a cause of death in patients with cancer and anticoagulant treatment has been shown to improve survival in a variety of cancers (Klerk et al. JCO. 2005).

PCI-27483 Factor VIIa Inhibitor

The Company�� Factor VIIa inhibitor PCI-27483 is a first-in-human small molecule inhibitor that selectively targets FVIIa. As an inhibitor of FVIIa, PCI-27483 has two potential mechanisms of action: inhibition of intracellular signaling involved in tumor growth and metastases and inhibition of early coagulation processes associated with thromboembolism.

Factor VIIa PCI-27483 Clinical Development Update

A multicenter Phase I/II of PCI-27483 in patients with locally a! dvanced o! r metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). The objectives are to assess the safety of FVIIa Inhibitor PCI-27483 at pharmacologically active dose levels, to assess potential inhibition of tumor progression and to obtain initial information of the effects on the incidence of thromboembolic events. Due to a paradigm shift away from the use of gemcitabine alone for the treatment of pancreatic cancer, enrolling patients in this randomized study has been challenging. PCYC is evaluating other alternatives for development of this agent.

A multicenter Phase I/II of PCI-27483 in patients with locally advanced or metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). PCI-27483 is covered by United States patents and patent applications and counterpart patents and patent applications in fourteen ex-United States territories, including Europe, Canada, Mexico, Japan, China, India, South Korea, Australia and Brazil.

Advisors' Opinion:

• [By Ben Levisohn]

  [The] sell-off in recent days was broad based and…affecting stocks in direct relationship to their volatility and expected duration of negative cash flow. Small and mid cap stocks were most affected (especially post-IPO stocks), and those with major uncertain events looming (MDVN) or with significant revenue upside already built into valuation (PCYC) were among the most severely affected. However, nothing changed in the environment to suggest that those events were any more or less likely to have positive outcomes yesterday, or to suggest that revenue potential was any more or less likely to be achieved than was previously expected.

• [By Sean Williams]

  We've witnessed first-hand what a crapshoot the space can be. Four years ago,�Pharmacyclics (NASDAQ: PCYC  ) looked like just another biotechnology company that was going to waste away into nothing with its share price trading for less than $1. In the years since, it's forged nearly a $1 billion licensing partnership with Johnson & Johnson (NYSE: JNJ  ) for its relapsed/refractory mantle cell lymphoma and chronic lymphocytic leukemia drug hopeful, Ibrutinib, and delivered some of the strongest overall response rates ever witnessed in trials for these two diseases. Shares of Pharmacyclics closed yesterday above $80 per share.

10 Best High Tech Stocks To Buy For 2014: InterOil Corp (IOC)

InterOil Corporation (InterOil), incorporated on August 24, 2007, is an integrated energy company operating in Papua New Guinea and the surrounding Southwest Pacific region. InterOil operates in four segments: upstream, midstream, downstream and corporate. The upstream segment explores, appraises and develops crude oil and natural gas structures in Papua New Guinea. This segment also manages its construction business, which services the development projects underway in Papua New Guinea. The midstream segment produces refined petroleum products at Napa Napa in Port Moresby, Papua New Guinea for the domestic market and for export. It is developing liquefaction and associated facilities in Papua New Guinea for the export of liquefied natural gas (LNG). The downstream segment markets and distributes refined products domestically in Papua New Guinea on a wholesale and retail basis.

During 2012, it sold approximately 13% of its refined petroleum products to Pacific Energy Aviation (PNG) Ltd for aviation refueling at Papua New Guinea�� international airport in Port Moresby. The corporate segment provides support to the other business segments by engaging in business development and improvement activities and providing general and administrative services and management, undertakes financing and treasury activities, and is responsible for government and investor relations. This segment also manages the Company�� shipping business, which operates two vessels transporting petroleum products for it�� and external customers, both within PNG and for export in the South Pacific region.

Upstream - Exploration and Production

InterOil�� upstream business segment focuses on the development program for the Elk, Antelope and Triceratops fields. The Elk and Antelope fields are onshore gas fields with contingent resources. As at December 31, 2012, it had interests in three PPLs and one PRL in Papua New Guinea covering 3,996,453 gross acres, all of which were operated by the Co! mpany. PPLs 236, 237 and 238 and PRL 15 are located onshore in the Eastern Papuan Basin, northwest of Port Moresby. It undertook exploration activities in its three exploration licenses, PPL 236, PPL 237 and PPL 238. These exploration activities involved a regional airborne geophysical survey, various seismic surveys across a number of prospects and preparation for drilling of its next appraisal well, Triceratops 2, which was spudded in mid-January 2012.

As of December 31, 2012, the Company had a 100% working interest in PPL 236. The license consists of 53 graticular blocks covering an area of 4,502 square kilometers or 1,112,464 acres. As of December 31, 2012, the Company had a 100% working interest in PPL 237. The license consists of 34 graticular blocks covering an area of 3,238 square kilometers or 715,648 acres. As of December 31, 2012, the Company had a 100% working interest in PPL 238. The license consists of 94 graticular blocks covering an area of 7,922 square kilometers or 1,978,565 acres.

Midstream

The Company�� refinery is located across the harbor from Port Moresby, the capital city of Papua New Guinea. Its refinery is the sole refiner of hydrocarbons located in Papua New Guinea. Jet fuel, diesel and gasoline are the primary products that the Company produces for the domestic market. The refining process also results in the production of two Naphtha grades and low sulfur waxy residue. Papua New Guinea is its principal market for the products its refinery produces, other than Naphtha and LSWR. Its refinery is fully certified to manufacture and market Jet A-1 fuel to international specifications and markets this product to both domestic Papua New Guinea and overseas airlines.

Downstream - Wholesale and Retail Distribution

The Company has the wholesale and retail petroleum product distribution base in Papua New Guinea. This business includes bulk storage, transportation distribution, aviation, wholesale and retail facilities! for refi! ned petroleum products. Its downstream business supplies petroleum products nationally in Papua New Guinea through a portfolio of retail service stations and commercial customers. As of December 31, 2012, InterOil provided petroleum products to 53 retail service stations with 43 operating under the InterOil brand name and the remaining 10 operating under their own independent brand. Of the 53 service stations that the Company supplies, 16 are either owned by or head leased to it, which it then sublease to company-approved operators. The remaining 37 service stations are independently owned and operated. It also provides fuel pumps and related infrastructure to the operators of the majority of these retail service stations that are not owned or leased by the Company under cover of equipment loan agreement. Its retail business accounted for approximately 15% of its total downstream sales during 2012. Its retail and wholesale distribution business distributes diesel, jet fuel, avgas, gasoline, kerosene and fuel oil, as well as branded commercial and industrial lubricants, such as engine and hydraulic oils.

The Company competes with ExxonMobil.

Advisors' Opinion:

• [By Lisa Levin]

  InterOil (NYSE: IOC) shares reached a new 52-week low of $50.60. InterOil's PEG ratio is -2.01.

  Linktone (NASDAQ: LTON) shares touched a new 52-week low of $1.30. Linktone's trailing-twelve-month operating margin is -20.15%.

10 Best High Tech Stocks To Buy For 2014: MEDNAX Inc (MD)

MEDNAX, Inc. (MEDNAX), incorporated in 2007, is a provider of physician services, including newborn, maternal-fetal, pediatric subspecialties and anesthesia care. As of December 31, 2011, the Company�� national network consisted of 1,839 affiliated physicians, including 996 physicians who provided neonatal clinical care, in 34 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. The Company has 190 affiliated physicians who provide maternal-fetal care to expectant mothers experiencing complicated pregnancies and obstetrical hospitalist services in many areas where its affiliated neonatal physicians practice. In March 2014, the Company acquired Piedmont Neonatology, P.C.Piedmont Neonatology, P.C, is a private neonatal physician group practice based in Greensboro, North Carolina.

MEDNAX�� network includes other pediatric subspecialists, including 108 physicians providing pediatric cardiology care, 85 physicians providing pediatric intensive care, 43 physicians providing hospital-based pediatric care and six physicians providing pediatric surgical care. In addition, it has 411 physicians who provide anesthesia care to patients in connection with surgical and other procedures, as well as pain management. The Company provides clinical care to babies born prematurely or with complications within specific units at hospitals, primarily NICUs, through a team of neonatal physician subspecialists (neonatologists), neonatal nurse practitioners and other pediatric clinicians. Neonatal nurse practitioners are nurses who have training and education in managing the healthcare needs of newborns, infants and their families.

MEDNAX provides outpatient and inpatient clinical care to expectant mothers and their unborn babies through its affiliated maternal-fetal medicine subspecialists, obstetricians and other clinicians, such as maternal-fetal nurse practitioners, nurse mid-wives, ultrasonogra! phers and genetic counselors. It provides inpatient and outpatient pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through its affiliated pediatric cardiologist subspecialists and other clinicians, such as pediatric nurse practitioners, echocardiographers and other diagnostic technicians, and exercise physiologists.

The Company�� network includes pediatric intensivists, who are hospital-based pediatricians with education and training in caring for critically ill or injured children and adolescents, pediatric hospitalists, who are hospital-based pediatricians specializing in inpatient care and management of acutely ill children and pediatric surgeons, who provide specialized care for patients ranging from newborns to adolescents, for all problems or conditions affecting children that require surgical intervention. Its affiliated physicians also provide clinical services in other areas of hospitals, particularly in the labor and delivery area and nursery and pediatric department.

The Company provides anesthesia care through a team of physician anesthesiologists, certified registered nurse anesthetists (CRNAs) and anesthesia assistants (AAs). The Company also provides acute and chronic pain management services. Postoperative acute pain management is often initiated in the hospital recovery room and may continue for the remainder of the hospital stay. Chronic pain services are offered through outpatient medical offices or hospital clinics.

Advisors' Opinion:

• [By Seth Jayson]

  MEDNAX (NYSE: MD  ) is expected to report Q2 earnings around July 30. Here's what Wall Street wants to see:

  The 10-second takeaway
  Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict MEDNAX's revenues will increase 18.4% and EPS will grow 11.5%.

• [By Bryan Murphy]

  Looking for some fresh trading ideas in a market environment that isn't offering many? Take a look at MEDNAX Inc. (NYSE:MD) and Westport Innovations Inc. (NASDAQ:WPRT). Though they're pointed in different directions, both MD and WPRT appear to be on the verge of trade-worthy moves. The fact that the two are nearly mirror images of one another is strictly coincidental.